A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

June 11, 2026 updated by: MediLink Therapeutics (Suzhou) Co., Ltd.

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
118

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Belgium
      • Namur, Belgium, 5000
        • Recruiting
        • Site 1201
        • Contact:
          • Study Coordinator
  • Italy
      • Meldola, Italy, 47014
        • Recruiting
        • Site 1703
        • Contact:
          • Study Coordinator
      • Ravenna, Italy, 48121
        • Recruiting
        • Site 1702
        • Contact:
          • Study Coordinator
  • Poland
      • Otwock, Poland, 05-400
        • Recruiting
        • Site 1802
        • Contact:
          • Study Coordinator
      • Poznan, Poland, 60-569
        • Recruiting
        • Site 1804
        • Contact:
          • Study Coordinator
      • Przemyśl, Poland, 37-700
        • Recruiting
        • Site 1801
        • Contact:
          • Study Coordinator
  • Romania
      • Craiova, Romania, 109
        • Recruiting
        • Site 1901
        • Contact:
          • Study Coordinator
  • Spain
      • Badajoz, Spain, 06080
        • Recruiting
        • Site 2013
        • Contact:
          • Study Coordinator
      • Barcelona, Spain, 08017
        • Recruiting
        • Site 2014
        • Contact:
          • Study Coordinator
      • Barcelona, Spain, 08023
        • Recruiting
        • Site 2003
        • Contact:
          • Study Coordinator
      • Madrid, Spain, 28034
        • Recruiting
        • Site 2002
        • Contact:
          • Study Coordinator
      • Madrid, Spain, 28040
        • Recruiting
        • Site 2005
        • Contact:
          • Study Coordinator
      • Madrid, Spain, 28223
        • Recruiting
        • Site 2004
        • Contact:
          • Study Coordinator
      • Madrid, Spain, 28850
        • Recruiting
        • Site 2011
        • Contact:
          • Study Coordinator
      • Manresa, Spain, 08242
        • Recruiting
        • Site 2010
        • Contact:
          • Study Coordinator
      • Valencia, Spain, 46010
        • Recruiting
        • Site 2009
        • Contact:
          • Study Coordinator
      • Valencia, Spain, 46026
        • Recruiting
        • Site 2015
        • Contact:
          • Study Coordinator
  • United Kingdom
      • London, United Kingdom, W12 0HS
        • Recruiting
        • Site 2201
        • Contact:
          • Study Coordinator
  • United States
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20057
        • Not yet recruiting
        • Site 1001
        • Contact:
          • Study Coordinator
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Recruiting
        • Site 1004
        • Contact:
          • Study Coordinator
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • Site 1005
        • Contact:
          • Study Coordinator
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Recruiting
        • Site 1002
        • Contact:
          • Study Coordinator

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

1.18 years of age or older. 2. Histologically or cytologically confirmed diagnosis of ES-SCLC 3. Eastern Cooperative Oncology Group performance status of 0 or 1 4. Adequate hematologic and end-organ function

Exclusion Criteria:

  1. No prior systemic anti-cancer treatment for ES-SCLC
  2. No prior treatment targeting B7H3 or topoisomerase I inhibitor
  3. No clinically active brain metastases or spinal cord compression
  4. No current or history of interstitial lung disease (ILD)/ pneumonitis
  5. No clinically significant cardiovascular disease (eg, New York Heart Association class II to IV congestive heart failure)

Other protocol-defined inclusion/ exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: YL201 1.2mg/kg in combination with atezolizumab 1200mg Q3W
Drug: YL201
YL201 intravenous infusion will be administered on Day 1 of each 21-day cycle.
Drug: Atezolizumab
Atezolizumab intravenous infusion will be administered at a dose of 1200 mg on Day 1 of each 21-day cycle
Experimental: YL201 1.6mg/kg in combination with atezolizumab 1200mg Q3W
Drug: YL201
YL201 intravenous infusion will be administered on Day 1 of each 21-day cycle.
Drug: Atezolizumab
Atezolizumab intravenous infusion will be administered at a dose of 1200 mg on Day 1 of each 21-day cycle
Experimental: YL201 2.0mg/kg in combination with atezolizumab 1200mg Q3W
Drug: YL201
YL201 intravenous infusion will be administered on Day 1 of each 21-day cycle.
Drug: Atezolizumab
Atezolizumab intravenous infusion will be administered at a dose of 1200 mg on Day 1 of each 21-day cycle

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Nature and Frequency with Dose-Limiting Toxicities (DLTs)
Time Frame: 21 days
21 days
Adverse Events
Time Frame: First dose of study treatment up to disease progression or death from any cause (up to approximately 6 years)
Incidence, nature, and severity of AEs graded according to the NCI CTCAE v5
First dose of study treatment up to disease progression or death from any cause (up to approximately 6 years)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
OS
Time Frame: Up to approximately 3 years
Up to approximately 3 years
ORR
Time Frame: Up to approximately 3 years
Up to approximately 3 years
DOR
Time Frame: Up to approximately 3 years
Up to approximately 3 years
PFS
Time Frame: Up to approximately 3 years
Up to approximately 3 years
AUC
Time Frame: Up to approximately 3 years
Up to approximately 3 years
CL
Time Frame: Up to approximately 3 years
Up to approximately 3 years
Vss
Time Frame: Up to approximately 3 years
Up to approximately 3 years
t1/2
Time Frame: Up to approximately 3 years
Up to approximately 3 years
Cmax
Time Frame: Up to approximately 3 years
Up to approximately 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
MediLink Therapeutics (Suzhou) Co., Ltd.

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Hoffmann-La Roche
Genentech, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 31, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 15, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 11, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • YL201-INT-102-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma

Clinical Trials on YL201

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings